In April 2025, Isomorphic Labs raised a $600 million in its first-ever external funding round, led by Thrive Capital. Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed ...

eSpeaks host Corey Noles sits down with Qualcomm's Craig Tellalian to explore a workplace computing transformation: the rise of AI-ready PCs. Matt Hillary, VP of Security and CISO at Drata, details ...

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised external capital for the first time. The $600 million round was led by Thrive Capital, with ...

Artificial intelligence (AI)-based drug developer Isomorphic Labs said it has raised $600 million in its first external funding round, with the proceeds expected to accelerate its research and ...

Isomorphic Labs raised $600 million in its first external funding round to boost its artificial-intelligence drug design pipeline across multiple therapeutic areas.

London-based Isomorphic Labs Ltd., a drug discovery-focused artificial intelligence startup that was spun out of Google LLC’s DeepMind unit just over two years ago, today announced key partnerships ...

Isomorphic Labs, Google’s artificial intelligence drug business, raised $600 million in its first external funding round, the company said on Monday. Thrive Capital, a venture capital firm, led the ...

Just more than two years after launching within Alphabet, Isomorphic has inked two large pharma deals with Eli Lilly and Novartis with nearly $3 billion in combined deal value. The two separate pacts ...

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. As Isomorphic Labs aims its artificial ...

Isomorphic Labs, a London-based spin-out of Alphabet Inc (NASDAQ:GOOG) (NASDAQ:GOOGL) Google's AI R&D division DeepMind, has announced strategic partnerships with Eli Lilly And Co (NYSE:LLY) and ...